Long-acting b-agonists (LABAs) were originally approved for the treatment of asthma in the
early 1990s. Despite nearly 20 years of experience with these medications, there is a storm …

The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

The uncertainty regarding the safety of longacting b-agonists (LABAs) in the treatment of
asthma has been lingering for the last 25 years, an ongoing concern for patients, clinicians …

This action is the most recent in a long history of concerns and controversies about the
safety of these agents. The changes are based on FDA's analyses of studies that …

The report by Salpeter and colleagues in this issue is a new entrant in the debate about long-
acting β-agonists and asthma. The investigators found that use of long-acting β-agonists …

The introduction of long-acting beta agonists (LABAs) was considered a major advance in
bronchodilator therapy with evidence that their use led to improved lung function and quality …

The regular therapeutic use of betaadrenergic agonists as bronchodilators in asthma has
been questioned (1). The current debate has been triggered by recent reports of adverse …

Safety of Long-Acting Beta-Agonists — An Urgent Need to Clear the Air | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

SABA monotherapy in mild asthma remained as the last example of guideline-
recommended bronchodilator therapy delivered without concomitant anti-inflammatory ICS …

Several studies suggested an association between the regular use of β 2-agonists and
asthma deaths. Whether this association represents adverse effects of β-agonist use or is …